Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Alaunos Therapeutics (TCRT) over the last 14 years, with Q3 2025 value amounting to $1.0 million.

  • Alaunos Therapeutics' Non-Current Assets changed N/A to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 15435000.0%. This contributed to the annual value of $2000.0 for FY2023, which is 9998.2% down from last year.
  • Alaunos Therapeutics' Non-Current Assets amounted to $1.0 million in Q3 2025.
  • Over the past 5 years, Alaunos Therapeutics' Non-Current Assets peaked at $17.4 million during Q2 2021, and registered a low of $2000.0 during Q4 2023.
  • Moreover, its 4-year median value for Non-Current Assets was $11.1 million (2022), whereas its average is $9.8 million.
  • As far as peak fluctuations go, Alaunos Therapeutics' Non-Current Assets soared by 13670.22% in 2021, and later tumbled by 9998.2% in 2023.
  • Over the past 4 years, Alaunos Therapeutics' Non-Current Assets (Quarter) stood at $16.0 million in 2021, then plummeted by 30.54% to $11.1 million in 2022, then crashed by 99.98% to $2000.0 in 2023, then soared by 51850.0% to $1.0 million in 2025.
  • Its Non-Current Assets was $1.0 million in Q3 2025, compared to $997000.0 in Q2 2025 and $1.1 million in Q1 2025.